trending Market Intelligence /marketintelligence/en/news-insights/trending/ye9UOWkogrHln2kDLTYfxQ2 content esgSubNav
In This List

Abbott's board approves $3B stock buyback

Blog

Insight Weekly: Private equity slows; SPAC underwriters retreat; carbon capture boost

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms


Abbott's board approves $3B stock buyback

The board of Abbott Laboratories has approved a buyback for up to $3 billion worth of outstanding common shares.

The latest repurchase is in addition to an unused $795 million buyback program that was issued by the Abbott Park, Ill.-based medical-device maker's board in September 2014.

Abbott, which manufactures cardiovascular, diabetes and other devices, recently received U.S. Food and Drug Administration approval for the Architect Stat High Sensitivity Troponin-I blood test. The device helps detect a heart attack faster.